Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of EGFR mutations and receiving first-line tyrosine kinase inhibitors: brain metastasis and de novo T790M matters

Fig. 3

Survival outcomes stratified by EGFR mutation subtypes. A Overall survival difference had been seen between patients with 19del and with L858R, but not be seen between patients with uncommon and with 19del or L858R. B There was no differences between patients with uncommon and with 19del or L858R in terms of progression free survival

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us